Normal Th1 development following long-term therapeutic blockade of CD154-CD40 in experimental autoimmune encephalomyelitis
J. Clin. Invest. Laurence M. Howard, et al. 109:233 doi:10.1172/JCI14374 [
Go to this article.]
Figure 5Short-term anti-CD154 therapy does not affect the early expression of homing receptors on OVA323-339–specific transgenic T cells in the draining lymph node. Five million DO11.10 transgenic OVA323-339–specific T cells were transferred to naive BALB/c recipients, and the recipients were immunized with 500 μg of OVA323-339/CFA and treated with either control Ig or anti-CD154 as described in Methods. Three days after immunization, lymph node cells were obtained and flow cytometric analysis of homing receptors evaluated ex vivo on KJ1-26 cells. Antigens critical for T cell entry into the CNS (CD44 and CD49d;
a and
b) and into the lymph node (CD62L;
c), and IL-12–dependent homing receptors (E- and P-selectin ligands;
d and
e), were evaluated. Control antibody staining is indicated by the dashed line, staining in control Ig–treated mice by the black line, and staining in anti-CD154–treated mice by the gray line. Data are representative of three separate experiments.
